Skip to main content
impaact logo Return to homepage
  • Contact
    • Directory
  • About
    • Mission
    • Network Structure
      • Leadership
    • Areas of Research
      • HIV Complications and Co-Morbidities
      • HIV Cure
      • HIV Treatment
      • Tuberculosis
      • Social Behavioral Scientific Core (SBSC)
    • Funding Acknowledgements
    • Network Sites
      • Site Map
    • Staff Spotlights
  • Studies
    • Research and Study Opportunities
    • Submit a Research Proposal
    • IMPAACT Study Snapshots
  • Community Engagement
    • ICAB Leadership Group
    • IMPAACT Community Advisory Board (ICAB)
    • Operations Center Staff
    • Resources
      • Acronyms
    • Site Community Advisory Boards
    • Community Meetings and Webinars
  • News & Events
    • Events and Conferences
    • IMPAACT Annual Meeting
    • Newsletters
    • Past Conference Presentations
  • Resources
    • COVID-19 Resources
    • HIV/AIDS Network Coordination (HANC)
    • Lab Center
      • Laboratory Committees
      • Laboratory Guidance Documents
      • Laboratory Resources for Quality Management
      • MiLab Resources
      • Specimen Repository
    • Manual of Procedures
    • Media Release Form
    • Network Logos & Templates
    • Regulatory Resources
    • Training Opportunities
    • NIH Updates
  • Publications
    • Abstracts
    • Manuscripts
  • Enter a search term.
Back to Directory

Mark Cotton

Email

mcot@sun.ac.za

Phone

27-21-938-4219

Institution

Stellenbosch Univ. CRS Tygerberg Hospital

Title

Principal Investigator

Address

University of Stellenbosch - Tygerberg Hospital
University of Stellenbosch
KID-CRU/J8
Francie van Zyl Drive, PO Box 19063
Parow Valley
Cape Town
Western Cape, 7505
South Africa
Request an Update

Affiliated Studies

IMPAACT 2039: Phase I/II Study of the Safety, Immunogenicity, and Efficacy of HIVconsvX Vaccines and Broadly Neutralizing Antibodies in Children Living with HIV

DAIDS Number

TBD

Research Area

Cure

Study Status

In Development

IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP)

DAIDS Number

38846

Research Area

Tuberculosis

Study Status

Pending

P1100: AERAS 402

DAIDS Number

11801

Research Area

Tuberculosis

Study Status

Concluded

P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls

DAIDS Number

11878

Research Area

Complications & Comorbidities

Study Status

Participants Off Study and Primary Analysis Completed

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

DAIDS Number

11882

Research Area

Treatment

Study Status

Closed to Follow Up
Show All
IMPAACT logo Return to homepage

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.

Stay connected with the IMPAACT Network

Follow IMPAACT

Sign up for our newsletter

Sitemap

© 2020 IMPAACT Network